PL1896489T3 - Sole albo kompleksy donorów grupy metylowej z kwasem fitynowym albo jego pochodnymi oraz sposób ich syntezy - Google Patents

Sole albo kompleksy donorów grupy metylowej z kwasem fitynowym albo jego pochodnymi oraz sposób ich syntezy

Info

Publication number
PL1896489T3
PL1896489T3 PL06766355T PL06766355T PL1896489T3 PL 1896489 T3 PL1896489 T3 PL 1896489T3 PL 06766355 T PL06766355 T PL 06766355T PL 06766355 T PL06766355 T PL 06766355T PL 1896489 T3 PL1896489 T3 PL 1896489T3
Authority
PL
Poland
Prior art keywords
phytic acid
salts
methyl donors
complexes
synthesis
Prior art date
Application number
PL06766355T
Other languages
English (en)
Inventor
Luca Maria De
Original Assignee
Luca Maria De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luca Maria De filed Critical Luca Maria De
Publication of PL1896489T3 publication Critical patent/PL1896489T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Seasonings (AREA)
PL06766355T 2005-06-30 2006-06-23 Sole albo kompleksy donorów grupy metylowej z kwasem fitynowym albo jego pochodnymi oraz sposób ich syntezy PL1896489T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000344A ITRM20050344A1 (it) 2005-06-30 2005-06-30 Sali o complessi di sostanze metil-donatrici con acido fitico o suoi derivati e relativo metodo di sintesi.
PCT/IT2006/000484 WO2007004244A1 (en) 2005-06-30 2006-06-23 Salts or complexes of methyl donors with phytic acid or its derivatives and method for the synthesis thereof
EP06766355A EP1896489B1 (en) 2005-06-30 2006-06-23 Salts or complexes of methyl donors with phytic acid or its derivatives and method for the synthesis thereof

Publications (1)

Publication Number Publication Date
PL1896489T3 true PL1896489T3 (pl) 2009-06-30

Family

ID=39033793

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06766355T PL1896489T3 (pl) 2005-06-30 2006-06-23 Sole albo kompleksy donorów grupy metylowej z kwasem fitynowym albo jego pochodnymi oraz sposób ich syntezy

Country Status (14)

Country Link
US (1) US8293254B2 (pl)
EP (1) EP1896489B1 (pl)
JP (2) JP4589999B2 (pl)
KR (1) KR101346974B1 (pl)
AT (1) ATE419256T1 (pl)
CY (1) CY1108929T1 (pl)
DE (1) DE602006004588D1 (pl)
DK (1) DK1896489T3 (pl)
ES (1) ES2320489T3 (pl)
IT (1) ITRM20050344A1 (pl)
PL (1) PL1896489T3 (pl)
PT (1) PT1896489E (pl)
SI (1) SI1896489T1 (pl)
WO (1) WO2007004244A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20060026A1 (it) 2006-01-10 2007-07-11 Truffini & Regge Farmaceutici Srl Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
US9236938B2 (en) 2006-07-07 2016-01-12 Telefonaktiebolaget L M Ericsson (Publ) Resource allocation for co-existing networks
ITMI20071374A1 (it) * 2007-07-10 2009-01-11 Gnosis Spa Sali stabili di s-adenosilmetionina e processo per il loro ottenimento.
JP4598846B2 (ja) * 2008-07-14 2010-12-15 磐田化学工業株式会社 S−アデノシルメチオニン安定化のためのフィチン酸および/またはデキストリンを含む飲食用組成物
IT1393331B1 (it) * 2009-02-09 2012-04-20 Graal S R L Composizioni orosolubili e/o effervescenti contenenti almeno un sale di s-adenosilmetionina (same)
JP5573587B2 (ja) 2010-10-20 2014-08-20 株式会社デンソー 車両用回転電機
EP2945959B1 (en) 2013-01-16 2020-05-13 Hebert Sam-E LLC Stable indole-3-propionate salts of s-adenosyl-l-methionine
ES2486441B1 (es) * 2014-04-02 2015-06-11 Universitat De Les Illes Balears Preparaciones combinadas de acidificantes urinarios e inhibidores de la cristalización y su aplicación para el tratamiento o prevención de la litiasis renal fosfática o inducida por fosfato cálcico
CA3208241A1 (en) * 2015-08-31 2017-03-09 Nutramax Laboratories, Inc. Compositions comprising magnolia, phellodendron, theanine and/or whey protein
IT201700074957A1 (it) 2017-07-04 2019-01-04 Gnosis Spa Sale di (ss)-adenosil metionina con inositolo esafosfato e procedimento per ottenerlo
FR3068602B1 (fr) * 2017-07-10 2020-11-20 Guy Parc Nouveau traitement du cancer par une combinaison d'un derive phosphorique d'inositol et de chlorure de magnesium
EP3556398A1 (en) * 2018-04-16 2019-10-23 Croda Denmark A/S Phytates for use as a biomolecules delivery or adsorption system
JP2021046375A (ja) * 2019-09-19 2021-03-25 ポッカサッポロフード&ビバレッジ株式会社 β3アドレナリン受容体活性化剤
CN115572309B (zh) * 2022-09-20 2024-05-03 浙江工业大学 一种高效阻燃、抗熔滴的环境友好型阻燃剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2824869A (en) * 1954-08-04 1958-02-25 Bristol Lab Inc Salt of streptomycin and phytic acid
US3019226A (en) * 1959-04-10 1962-01-30 Olin Mathieson Piperazine salt of phytic acid
US3242235A (en) * 1963-06-13 1966-03-22 Squibb & Sons Inc Phytate salts of the tetracyclines
IE39517B1 (en) * 1973-06-27 1978-10-25 Bioresearch Sas Double salts of s-adenosyl-l-methhionine
IT1200589B (it) * 1985-02-14 1989-01-27 Gibipharma Spa Derivati naturali attivita farmagologica
JPH0215032A (ja) * 1988-07-01 1990-01-18 Sanwa Kagaku Kenkyusho Co Ltd 肝疾患治療、予防剤及び強肝機能性飲食、し好物
US5434144A (en) * 1994-03-04 1995-07-18 The Procter & Gamble Company Methods of using cyclic polyanionic polyol derivatives for regulating skin wrinkles
IT1318535B1 (it) * 2000-05-25 2003-08-27 Chementecno Srl Processo per la preparazione di sali farmaceuticamente accettabili di(ss,rs)-s-adenosil-l-metionina.
US20030069202A1 (en) * 2000-06-02 2003-04-10 Kern Kenneth Norman Compositions, kits, and methods for promoting defined health benefits
US6610702B2 (en) * 2000-08-01 2003-08-26 Gmp Oxycell, Inc. Ammonium salts of inositol hexaphosphate, and uses thereof
JP2002145783A (ja) * 2000-11-06 2002-05-22 Kohjin Co Ltd S−アデノシルメチオニンまたはその塩類を含有するカプセル製剤
US20030078231A1 (en) * 2001-06-22 2003-04-24 Wilburn Michael D. Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
WO2003087109A1 (en) * 2002-04-12 2003-10-23 Silbiotec Due S.A. Medicaments containing glycerophosphoinositol-4-phosphate derivatives
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
ATE424848T1 (de) * 2004-08-12 2009-03-15 Quest Pharmaceutical Services Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease

Also Published As

Publication number Publication date
WO2007004244A1 (en) 2007-01-11
US20090175914A1 (en) 2009-07-09
JP2009500319A (ja) 2009-01-08
SI1896489T1 (sl) 2009-06-30
ITRM20050344A1 (it) 2007-01-01
DK1896489T3 (da) 2009-04-20
DE602006004588D1 (de) 2009-02-12
ES2320489T3 (es) 2009-05-22
JP5283659B2 (ja) 2013-09-04
PT1896489E (pt) 2009-04-01
JP2010235616A (ja) 2010-10-21
JP4589999B2 (ja) 2010-12-01
US8293254B2 (en) 2012-10-23
KR20080028949A (ko) 2008-04-02
EP1896489A1 (en) 2008-03-12
ATE419256T1 (de) 2009-01-15
KR101346974B1 (ko) 2014-01-02
EP1896489B1 (en) 2008-12-31
CY1108929T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
CY1108929T1 (el) Αλατα ή συμπλοκα δοτων μεθυλιου με φυτικο οξυ ή τα παραγωγα αυτου και μεθοδος για τη συνθεση αυτων
UA93225C2 (ru) 3'-алкоксиспироциклопентилзамещенные производные тетрамовой кислоты и гербицидное средство ha их ochobe
WO2007133183A3 (en) Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
MX2009003521A (es) Uso de ph bajo para modificar la textura de productos de proteina vegetal estructurada.
BRPI0607633A2 (pt) mistura de oligossacarìdeo
ATE447564T1 (de) Zwischenprodukte für die herstellung von trans-5- chlor-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenzä , 3:6,7üoxepinoä4,5-cüpyrrol
CY1111045T1 (el) Μεθοδος παραγωγης ενος παραγωγου βενζιμιδαζολιου
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
MX2007008790A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso.
DE502006008627D1 (de) Verfahren zur herstellung ortho-metallierter metallverbindungen
MY148182A (en) Method of relating different products by a common feature
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
DK1978823T3 (da) Sammensætninger og fremgangsmåde til at fremme fedttab
WO2007147163A3 (en) Compositions comprising carotenoid analogs or derivatives and methods for synthesis
AR058348A1 (es) Derivados de 1-aza-biciclo-nonano y composiciones farmaceuticas que los comprenden
WO2007133184A3 (en) Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors
MX2009003459A (es) Derivados de 2,3,3-trimetilciclopent-3-encarbaldehido utiles como odorantes.
ATE485261T1 (de) Salicylsäurederivate
DE602005020185D1 (de) Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4henprodukte für dieses verfahren
TW200613270A (en) Ionic liquids having fluoroalkyltrifluoroborate anions
ATE452120T1 (de) Fettsäure-benzenediol-derivate sowie herstellungs-und verwendungsverfahren dafür
TW200716664A (en) Immunoglobulin fraction and process therefor
EA200870236A1 (ru) Моногидрат римонабанта, способ его получения и фармацевтические композиции на его основе